Study: NCT02851095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.